BioCentury
ARTICLE | Company News

Valeant Pharmaceuticals International deal

October 5, 2009 7:00 AM UTC

Valeant bought out the income rights and milestone obligations owed to former shareholders of Dow Pharmaceutical Sciences Inc. for $115 million. Under the deal, Valeant is released from $235 million ...